Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FABP4 | P15090 | 7/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 7/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5516368 | 1.00 | SMN1; SMN2 (0.32) | SMN1; SMN2FABP4FABP5HSD11B1POLB | |
| SCHEMBL5955871 | 0.80 | DPP4 (0.37) | FABP4FABP5HSD11B1POLBCA1 | |
| SCHEMBL5525299 | 0.77 | SMYD3 (0.42) | CA1CA2CA9KLK7 | |
| SCHEMBL5525293 | 0.77 | SMYD3 (0.42) | CA1CA2CA9KLK7 | |
| SCHEMBL5526079 | 0.77 | SMYD3 (0.42) | CA1CA2CA9KLK7 | |
| SCHEMBL17897216 | 0.74 | FABP4 (0.36) | FABP4FABP5HSD11B1POLBCA1 | |
| SCHEMBL6433614 | 0.72 | CA1 (0.40) | FABP4FABP5HSD11B1POLBCA1 | |
| SCHEMBL14427060 | 0.72 | FABP4 (0.33) | FABP4FABP5HSD11B1POLB | |
| SCHEMBL17898050 | 0.69 | PIK3CG (0.36) | FABP4FABP5HSD11B1POLBCA1 | |
| SCHEMBL6207925 | 0.68 | CA1 (0.35) | FABP4FABP5HSD11B1POLBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | claimed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | claimed |
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | disclosed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSF | SMN1; SMN2 2512/4885FABP4 1378/4885FABP5 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.